Our Platform · Results
HERMS connects 25 specialist applications across discovery, development, manufacturing, regulation, access, safety, supply and capital. Each produces structured, source-linked outputs that your experts can review, challenge and act on.
Result Types
Four result types, each designed around a specific decision your team has to make.
A structured synthesis of what the evidence shows, where sources agree and where gaps remain.
Supports: whether the evidence is sufficient to proceed.
A criterion-by-criterion view of how prepared a program, process or submission is.
Supports: whether to advance, remediate or pause.
Options set side by side with stated assumptions, trade-offs and uncertainty.
Supports: which path to pursue.
Prioritized steps with named owners, linked to the findings that triggered them.
Supports: what to do next and who is accountable.
Representative Outputs
Six assessment families, each producing defined deliverables that feed a named decision.
Connects target biology, vector or editing design, delivery and safety evidence in one reviewable view.
Decision: whether and how to advance a program.
Tests whether process knowledge, IP rights and site capability are ready to transfer.
Decision: whether to proceed with a transfer.
Examines process design, control strategy and quality evidence against stated requirements.
Decision: what to resolve before scale-up or release review.
Links regulatory obligations with pricing, tender and payer evidence needs, market by market.
Decision: submission and market-entry strategy.
Brings safety signals and supply risks into one prioritized view.
Decision: where to intervene first to protect patients and availability.
Converts scientific, regulatory, manufacturing and market evidence into comparable capital options.
Decision: where to allocate or hold capital.
Demonstrated Work
No completed-project case study is published here. The structure below shows how each one will be documented once supported by evidence.
The decision the team faced and why existing evidence was hard to review.
Applications, products, markets and questions covered, and what was excluded.
Source types, volume and provenance, listed so reviewers can check coverage.
The assessment, registers and plan handed to the accountable team.
Who reviewed the output, by what method, and what they changed.
Open gaps, assumptions and conditions under which conclusions should not be relied on.
Measuring Results
An output is what HERMS delivers. An outcome is what an independent measure shows. Each measure below is set against a baseline agreed before work begins.
Required evidence items present, against the checklist agreed at kickoff.
Elapsed time from evidence submission to reviewer-ready output, against the team's current process.
Issues raised, closed and reopened over an agreed period, against the starting position.
Conclusions linked to a citable source, confirmed by sampled reviewer checks.
Criteria met at each milestone gate, against the agreed plan.
No results are reported until a baseline is agreed and measurement is independently reviewed.
Human Review and Accountability
Each analytical conclusion travels with the information a reviewer needs to accept, amend or reject it.
Regulatory, clinical, manufacturing-release and investment decisions remain with appropriately authorized people. HERMS outputs inform those decisions. They are not regulatory approval, validated manufacturing readiness or investment authorization.
Start by agreeing the workflow, the deliverable, the evidence requirements and the acceptance criteria. We will show you how HERMS would produce it.
ENGINEERING INTELLIGENCE. REVOLUTIONIZING LIFE SCIENCES.
We use essential cookies to run this website and, with your consent, analytics cookies to improve it. You can change your choice at any time. Cookie Policy · Privacy Policy
HERMS is the intelligence platform. Its applications are the decision engines. HERMS expert services support implementation and regulated execution of the HERMS intelligence ecosystem, from regulatory and market access to pharmacovigilance, compliance and quality.